logo-loader
viewQ BioMed Inc.

Full interview: Q BioMed successfully synthesizes molecule to treat liver cancer in a 'tremendously exciting achievement'

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive that the New York-based biotech, together with India-based research organization Chemveda Life Sciences, has made a breakthrough with its therapy as a potential chemotherapy to treat liver cancer.

Corin says the molecule called Uttroside-B, is in pre-clinical development, and the company looks forward to submit it as an investigational new drug in 1Q of 2020.

Quick facts: Q BioMed Inc.

Price: 2.35 USD

OTCMKTS:QBIO
Market: OTCQB
Market Cap: $48.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed infuses first patient with its FDA-approved cancer...

Q BioMed Inc. (OTCQB:QBIO) CEO Denis Corin tells Proactive the New York-based biotech company, has dosed its first patient in a commercial setting with its FDA approved non-opioid drug Strontium89 for patients with pain from metastatic bone cancer. Corin says the company is working on making...

3 weeks ago

2 min read